|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Advocacy Group to FDA: Acid Reflux Drugs Should Have Black Box Warnings
8/24/2011 8:18:40 AM
Withdrawal from PPIs (proton pump inhibitors) can lead to severe rebound acid secretion, a complication that can force users to become dependent on them - this should be mentioned in a black-box warning, consumer group Public Citizen has told the FDA (Food and Drug Administration). Examples of PPIs include, Dexilant, Vimovo, Prilosec OTC, Prevacid 24-Hr, Zegerid, Zegerid OTC, Prevacid, Nexium, , Prilosec, Protonix, and Aciphex.
|
|
|
|
|
|
|
|
|
|
|